Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of oral HRS-5346 in adults at high cardiovascular risk with elevated lipoprotein(a)
CTR20250379Phase 2Completed
- Sponsor
- Shandong Sende
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MK-7262 in dyslipidemia, lipoprotein(a) hyperlipoproteinemia (Lp(a)), sponsored by Shandong Sende. Started Feb 2025; status: completed.
02
Drugs
MK-7262
03
Conditions
dyslipidemialipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on CTR20250379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250379.